Program Day One Friday, April 11th 2025 Day Two Saturday, April 12th 2025 07:30 am Registration & Breakfast 08:30 am Inaugural Programme Session I - Aplastic Anemia 09:00 am Advances in the Pathophysiology of Aplastic Anemia Neal Young National Heart, Lung and Blood Institute (NHLBI), USA 09:30 am Is it Prime Time for Thriple Therapy to become standard of care in Aplastic Anemia Phillip Scheinberg Hospital Beneficencia Portuguesa de Sao Paulo, Brazil. 10:00 am Immune Dysregulation and role of Regulatory cells in Aplastic Anemia Ghulam Mufti Kings College, London 10:30 am Morning break Session II - Lab Session I - Biology, Gene editing and diagnosis 11:00 am Fanconi Anemia and Telomeropathies 11:25 am Rare disease programme in India 11:50 am Disease modelling using IPSCS Shaji R Velayudhan Christian Medical College, Vellore, India 12:15 pm Title – TBA Eunice Sindhuvi CMC Vellore 12:40 pm Lunch and poster session Session III - Aplastic Anemia in children 02:00 pm Congenital Aplastic Anemia in children – How do I manage? Carlo Dufour IRCCS Giannina Gaslini, Genoa, Italy. 02:25 pm Immunosuppressive therapy in children with AA (Dual vs Thriple Therapy)) 02:50 pm Advances in the medical management of Fanconi Anemia Parinda Mehta 03:15 pm Genotype-Phenotype correlation in diamond balckfan anemia Neelam Giri National Cancer Institute, NIH, Bethesda, USA. 03:40 pm Managing children with AA – panel discussion 04:25 pm Tea Break Session IV – Aplastic Anemia in India 04:30 pm Generic equine ATG can replace ATGAM 04:40 pm Alternate donor transplant is the answer 04:50 pm Rabbit ATG is still useful 05:00 pm Oral drugs are probably the way to go 05:10 pm Questions and Answers Session V – Long term complications 05:30 pm Screening for early detection of cancer in FA and Telomere biology disorders Neelam Giri National Cancer Institute, NIH, Bethesda, USA. 06:00 pm Clonal evolution following use of TPO Agonists – Should we be worried? Phillip Scheinberg Hospital Beneficencia Portuguesa de Sao Paulo, Brazil. 06:30 pm Long term complications following HSCT for AA in Children Parinda Mehta 07:00 pm Factors predicting transformation to MDS from AA Shreyans Gandhi Kings College Hospital NHS Foundation Trust, London, UK 07:30 pm Dinner 07:00 am Registration + Breakfast Session VI - Myelodysplastic Syndromes/PNH 08:00 am A morphologist’s approach to MDS 08:25 am Advances in the management of high risk MDS – Role of HMAs Austin Kulasekararaj King's College Hospital, London, UK. 08:50 am Impact of Germline and Somatic mutations in childhood MDS Marcin Wlodarski St. Jude Children's Research Hospital, Memphis, USA. 09:20 am Stem cell transplant for MDS – Who, Where, Why? Shreyans Gandhi Kings College Hospital NHS Foundation Trust, London, UK 09:50 am Complement inhibitors and HSCT in PNH – Current status Austin Kulasekararaj King's College Hospital, London, UK. 10:20 am Break Session VII - Aplastic anemia - Indian perspective/Supportive care 10:50 am Management of AA in India – AIIMS Perspective 11:15 am Stem cell transplantation for AA in adults 11:40 am Is oral therapy for AA relevant in India 12:20 pm Bacterial and Fungal infections in Aplastic Anemia Sharon Lionel CMC Vellore 12:45 pm TBC 01:10 pm Lunch Session VIII - Aplastic anemia - Session II 02:00 pm Stem cell transplantation for paediatric AA Carlo Dufour IRCCS Giannina Gaslini, Genoa, Italy. 02:30 pm Haploidentical transplants for Fanconi Anemia Carmem Bonfim 03:00 pm How far have we come in predicting response to immunosuppressive therapy? Ghulam Mufti Kings College, London 03:30 pm Future therapies for immune aplastic anemia Neal Young National Heart, Lung and Blood Institute (NHLBI), USA 04:00 pm Closing ceremony followed by tea Close
